Fast Market Research announces the availability of the new Global Markets Direct report, "Asthma - Pipeline Review, H1 2016", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 06/03/2016 -- Global Markets Direct's, 'Asthma - Pipeline Review, H1 2016', provides an overview of the Asthma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Asthma and features dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get More Details on this Report and a Full Table of Contents at Asthma - Pipeline Review, H1 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
-The report provides a snapshot of the global therapeutic landscape of Asthma
-The report reviews pipeline therapeutics for Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved Asthma therapeutics and enlists all their major and minor projects
-The report assesses Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news related to pipeline therapeutics for Asthma
Reasons to Get This Report
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand important and diverse types of therapeutics under development for Asthma
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned in this Report: 4D Pharma Plc, AB Science SA, Abeome Corporation, Accolade Pharmaceuticals, LLC, Acorda Therapeutics, Inc., Adamis Pharmaceuticals Corporation, Advinus Therapeutics Ltd., Afferent Pharmaceuticals, Inc., ALK-Abello A/S, Allergopharma GmbH & Co. KG, Almirall, S.A., Amakem NV, Amgen Inc., AnaptysBio, Inc., Antisense Therapeutics Limited, Aquinox Pharmaceuticals Inc., ARA Healthcare Pvt. Ltd., Ario Pharma Ltd, ASIT biotech s.a., Aslan Pharmaceuticals Pte. Ltd., Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Aurigene Discovery Technologies Limited, Axikin Pharmaceuticals, Inc., Baxalta Incorporated, Bioncotech Therapeutics S.L., Biotec Pharmacon ASA, Boehringer Ingelheim GmbH, Caladrius Biosciences, Inc., CalciMedica, Inc., Carolus Therapeutics, Inc., Cellceutix Corporation, Cellular Biomedicine Group, Inc., Celon Pharma Sp. z o.o., Chiesi Farmaceutici SpA, Chong Kun Dang Pharmaceutical Corp., Circassia Pharmaceuticals Plc, Cognosci, Inc., CSL Limited, Cumberland Pharmaceuticals, Inc., Cytokinetics, Inc., Daiichi Sankyo Company, Limited, Dynavax Technologies Corporation, F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Foresee Pharmaceuticals, LLC, Fountain Biopharma Inc., Genentech, Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., GliaCure Inc., Griffin Discoveries BV, Hanmi Pharmaceuticals, Co. Ltd., Hydra Biosciences, Inc., iCeutica, Inc., iCo Therapeutics Inc., Infinity Pharmaceuticals, Inc., INOXIA Lifesciences GmbH, Invion Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, Kineta, Inc., Kissei Pharmaceutical Co., Ltd., Kolltan Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd., Laboratoires Pierre Fabre SA, Lead Discovery Center GmbH, LegoChem Biosciences, Inc, Ligand Pharmaceuticals, Inc., Lpath, Inc., Marinomed Biotechnologie GmbH, MedImmune, LLC, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Mycenax Biotech Inc., NAL Pharmaceuticals Ltd., NeoPharm Co., Ltd., Nostrum Pharmaceuticals, LLC, Novartis AG, Omeros Corporation, Ono Pharmaceutical Co., Ltd., OPKO Health, Inc., Orbis Biosciences, Inc., Orion Oyj, Oxagen Limited, Palatin Technologies, Inc., Panacea Biotec Limited, Panmira Pharmaceuticals, LLC., Peptinnovate Limited, PharmaLundensis AB, Pharmaxis Limited, Plexxikon Inc., Polyphor Ltd., Promedior, Inc., Protectimmun GmbH, Pulmagen Therapeutics LLP, Re-Pharm Limited, Regeneron Pharmaceuticals, Inc., Respiratorius AB, ReveraGen BioPharma, Inc., Rhizen Pharmaceuticals S.A., Saje Pharma, LLC, SkyePharma Plc, Spring Bank Pharmaceuticals, Inc., Stallergenes SAS, sterna biologicals Gmbh & Co KG, Sumitomo Dainippon Pharma Co., Ltd., Sun Pharma Advanced Research Company Ltd., Sunovion Pharmaceuticals Inc., Swecure AB, Synovo GmbH, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The International Biotechnology Center (IBC) Generium, Therabron Therapeutics, Inc., Theraclone Sciences, Inc., Theravance Biopharma, Inc., Tolerys SA, UCB S.A., United BioPharma, Inc., Vectura Group Plc, Verona Pharma Plc, WhanIn Pharmaceutical Co., Ltd., Xencor, Inc., Yungjin Pharm. Co., Ltd., Zambon Company S.p.A., Ziarco Pharma Ltd
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-Allergic Asthma - Pipeline Review, H1 2016
-Allergic Rhinitis - Pipeline Review, H1 2016
-Atopic Dermatitis - Pipeline Review, H1 2016
-Myocardial Infarction - Pipeline Review, H1 2016
-Depression - Pipeline Review, H1 2016